Core Insights - New clinical and real-world data presented at ACC.26 reinforce the benefits of Vutrisiran for patients with ATTR-CM and highlight the potential of Zilebesiran for hypertension management [1][2][3] Vutrisiran Insights - Vutrisiran is the first and only TTR silencer that provides rapid knockdown of TTR at the source, showing significant improvements in health-related quality of life (QoL) for ATTR-CM patients, with effects comparable to those in patients over ten years younger [2][5][6] - The HELIOS-B analyses indicate that Vutrisiran leads to sustained benefits across various disease severities, demonstrating a 40% reduction in the risk of all-cause mortality and recurrent cardiovascular events in patients with advanced disease compared to placebo [7][8] - Real-world data show a high adherence rate of 93.8% among patients receiving Vutrisiran, with most patients continuing treatment after 12 months [8] Zilebesiran Insights - Zilebesiran is an investigational RNAi therapeutic aimed at reducing cardiovascular risk in patients with hypertension, showing a favorable safety profile in Phase 2 studies [3][11] - The ongoing ZENITH Phase 3 trial aims to evaluate Zilebesiran's efficacy in providing continuous blood pressure control, targeting angiotensinogen to manage hypertension effectively [10][17] Safety and Efficacy Data - Pooled safety data from Phase 2 studies indicate that Zilebesiran has an acceptable safety profile, with low incidences of clinically relevant safety events such as hypotension and hyperkalemia [11] - Vutrisiran's safety profile remains favorable, with no new safety issues identified in patients with advanced disease [15]

Core Insights - Vutrisiran treatment resulted in a 37-49% reduction in gastrointestinal (GI) events in patients with ATTR-CM compared to placebo, demonstrating its efficacy and safety across various patient groups [1][2][4] Group 1: Efficacy of Vutrisiran - A 42% lower rate of GI events was observed in the overall population treated with vutrisiran compared to placebo [2] - In the vutrisiran monotherapy group, a 37% reduction in GI events was noted, while a 49% reduction was seen in patients who were on tafamidis at baseline [2] - Significant reductions of over 50% in individual GI symptoms such as diarrhea, nausea, and vomiting were reported across all study populations [2] Group 2: Safety Profile - The analysis indicated that the lower rate of GI events was consistent across hereditary and wild-type patients throughout the double-blind period [2] - Vutrisiran demonstrated a statistically significant 32% reduction in the risk of all-cause mortality and recurrent cardiovascular events compared to placebo in a censored monotherapy population [4] Group 3: Clinical Implications - The findings highlight the potential of vutrisiran as a first-line treatment for ATTR-CM, addressing the multisystem nature of the disease [4][5] - The results reinforce the strong monotherapy profile of vutrisiran, suggesting meaningful impacts on patient quality of life and overall health outcomes [5][6] Group 4: Regulatory and Market Context - Vutrisiran has received approvals in multiple regions, including the US, EU, and Japan, for treating both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis [6][12] - The drug has accumulated over 8,000 patient-years of experience globally, establishing its position in the market [6]